Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cavrotolimod - Bluejay Therapeutics

Next Previous
Drug Profile

Cavrotolimod - Bluejay Therapeutics

Alternative Names: AST 008

Latest Information Update: 29 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exicure
  • Developer Bluejay Therapeutics; Exicure
  • Class Antineoplastics; Antivirals; Immunotherapies; Oligonucleotides
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hepatitis B
  • Discontinued Haematological malignancies; Merkel cell carcinoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 15 Nov 2024 Pharmacodynamics data from preclinical studies in Hepatitis B presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases cynomolgus monkeys (AASLD-2024)
  • 15 Nov 2024 Pharmacodynamics data from the preclinical studies in Hepatitis B released by Bluejay Therapeutics
  • 22 May 2024 Phase-I clinical trials in Hepatitis B (SC) (Bluejay Therapeutics pipeline; May 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top